A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

NCT06199336 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

190

Enrollment

NETWORK

Sponsor class

Conditions

Moderate to Severe Glabellar Lines

Interventions

BIOLOGICAL: JHM03
BIOLOGICAL: BOTOX®
BIOLOGICAL: Placebo

Sponsor

JHM BioPharma (Tonghua) Co. , Ltd.